Goodpoint Bio

Goodpoint Bio is a venture-backed biotechnology company focused on the discovery and development of next-generation small molecule therapeutics for oncology. Launched in May 2024 with an $80 million Series A commitment from Apple Tree Partners (ATP), the company aims to address high-value, historically "undruggable" targets in the cancer space. Goodpoint Bio utilizes an integrated platform that combines structural biology, chemical biology, and computational tools to identify novel binding sites and develop precision medicines. Led by a team of experienced oncology researchers from organizations like Novartis and MOMA Therapeutics, the company is primarily operating in the discovery and pre-clinical stages. Their approach includes the development of both traditional covalent inhibitors and innovative modalities such as molecular glues to treat patients with significant unmet needs.